ROS1 Treatment Options: Lorlatinib and Repotrectinib – 2022 Program: Targeted Therapies Forum

Dive into the ever-evolving world of ROS1+ treatment options with Dr. Alejandro Calvo. In this specialized session from the 2022 Targeted Therapies Forum, learn about the potential benefits of Lorlatinib and Repotrectinib for patients grappling with ROS1+ disease.

Our gratitude goes out to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.

Craving more insights on cutting-edge cancer treatments? Explore http://cancerGRACE.org/. Engage with our passionate community and renowned experts at https://cancergrace.org/forum.